KCTD15 and REN

Number of citations of the paper that reports this interaction (PubMedID 16169070)
888

Data Source:
BioGRID (two hybrid)
HPRD (two hybrid)

		KCTD15	REN
Description		potassium channel tetramerization domain containing 15	renin
Image		No pdb structure
GO Annotations	Cellular Component		Extracellular Region Extracellular Space Cytoplasm Plasma Membrane Apical Part Of Cell
	Molecular Function	Protein Binding Identical Protein Binding	Aspartic-type Endopeptidase Activity Signaling Receptor Binding Insulin-like Growth Factor Receptor Binding Protein Binding Peptidase Activity
	Biological Process	Protein Homooligomerization	Kidney Development Mesonephros Development Angiotensin Maturation Renin-angiotensin Regulation Of Aldosterone Production Proteolysis Regulation Of Blood Pressure Male Gonad Development Hormone-mediated Signaling Pathway Response To Lipopolysaccharide Response To Immobilization Stress Drinking Behavior Regulation Of MAPK Cascade Cell Maturation Amyloid-beta Metabolic Process Response To CAMP Response To CGMP Cellular Response To Xenobiotic Stimulus
Pathways		Negative regulation of activity of TFAP2 (AP-2) family transcription factors	Metabolism of Angiotensinogen to Angiotensins
Drugs			Remikiren Minoxidil Lisinopril N,N-dimethylformamide Isoamyl alcohol 3-Phenyl-1,2-Propandiol 2-Methyl-3-(2-Aminothiazolo)Propanal Enalkiren 2-Cyclopropylmethylenepropanal 1-Methyl-2-Oxy-5,5-Dimethyl Pyrrolidine N-Methyl-N-(Methylbenzyl)Formamide 1-Hydroxy-2-Amino-3-Cyclohexylpropane SPP1148 ZOTHIAZIN-4-YL]ETHYL}ACETAMIDE 6-ETHYL-5-[9-(3-METHOXYPROPYL)-9H-CARBAZOL-2-YL]PYRIMIDINE-2,4-DIAMINE N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOXAZIN-4-YL]ETHYL}ACETAMIDE (2S)-6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2-(3,5-DIFLUOROPHENYL)-4-(3-METHOXYPROPYL)-2H-1,4-BENZOXAZIN-3(4H)-ONE 6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-4-(3-METHOXYPROPYL)-2,2-DIMETHYL-2H-1,4-BENZOXAZIN-3(4H)-ONE 5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE 6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine Aliskiren
Diseases
GWAS		BMI (adjusted for smoking behaviour) ( 28443625) BMI in non-smokers ( 28443625) Body mass index ( 19079260 19079261 28892062 25673413 20935630 28448500) Body mass index (joint analysis main effects and physical activity interaction) ( 28448500) Body mass index (joint analysis main effects and smoking interaction) ( 28443625) Body mass index in physically active individuals ( 28448500) Dental caries (decayed and filled deciduous teeth) ( 31533690) Dental caries (decayed and filled deciduous tooth surfaces) ( 31533690) Disease progression in age-related macular degeneration ( 29346644) Major depressive disorder ( 23377640) Obesity-related traits ( 23251661) Response to antidepressants (symptom remission) ( 29160301) Response to SSRI (symptom remission) ( 29160301) Spherical equivalent or myopia (age of diagnosis) ( 29808027) Weight ( 19079260)	Blood protein levels ( 29875488) Blood protein levels in cardiovascular risk ( 28369058) Response to cognitive-behavioural therapy in anxiety disorder ( 31123309)
Interacting Genes		15 interacting genes: ATXN1 CYSRT1 ENSA KCTD1 KCTD21 NBPF19 NOTCH2NLA NOXA1 NTAQ1 REN TFAP2A TRIM27 TRIM55 TRIM63 WIPI1	9 interacting genes: AGT ATP6AP2 CCDC24 CTSB KCTD15 M6PR PCSK1 PCSK5 RENBP
Entrez ID		79047	5972
HPRD ID		13765	01564
Ensembl ID		ENSG00000153885	ENSG00000143839
Uniprot IDs		Q96SI1	P00797
PDB IDs			1BBS 1BIL 1BIM 1HRN 1RNE 2BKS 2BKT 2FS4 2G1N 2G1O 2G1R 2G1S 2G1Y 2G20 2G21 2G22 2G24 2G26 2G27 2I4Q 2IKO 2IKU 2IL2 2REN 2V0Z 2V10 2V11 2V12 2V13 2V16 2X0B 3D91 3G6Z 3G70 3G72 3GW5 3K1W 3KM4 3O9L 3OAD 3OAG 3OOT 3OQF 3OQK 3OWN 3Q3T 3Q4B 3Q5H 3SFC 3VCM 3VSW 3VSX 3VUC 3VYD 3VYE 3VYF 4AMT 4GJ5 4GJ6 4GJ7 4GJ8 4GJ9 4GJA 4GJB 4GJC 4GJD 4PYV 4Q1N 4RYC 4RYG 4RZ1 4S1G 4XX3 4XX4 5KOQ 5KOS 5KOT 5SXN 5SY2 5SY3 5SZ9 5T4S 5TMG 5TMK 5V8V 5VPM 5VRP 6I3F
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?